For decades, competition in healthcare contracting has been defined by one thing: price. Lowest price won tenders, shaped budgets, and guided procurement teams across Europe.

That reality is changing fast.

Across the European Union and the United Kingdom, the concept of “most economically advantageous tender” (MEAT) or “most advantageous tender” (MAT) has become the new legal default. These frameworks compel contracting authorities to evaluate bids based on quality, sustainability, and life-cycle value, not simply the cheapest offer.

This shift marks a structural, policy-driven invitation to monetise non-price strengths. The manufacturers and suppliers who can evidence clinical performance, resilience, digital integration, and environmental responsibility will increasingly outperform those competing on unit cost alone.

But identifying, quantifying, and anticipating how these non-price criteria (NPC) are scored requires a new level of intelligence. It demands that manufacturers and market access teams move beyond traditional bid-desk reactivity toward data-driven understanding of how buyers think and what they reward.

The Policy Inflection Point

A Pan-European Recalibration

The movement toward non-price evaluation is not an abstract ideal; it is codified in law. The European Union’s procurement directives, transposed across member states, require contracting authorities to consider social, environmental, and innovation factors in award decisions.

New digital eForms and structured publication standards under the TED data model now capture award criteria, weights, and even sub-criteria in machine-readable form. This creates unprecedented transparency into how contracting bodies assign value across categories and over time.

The UK’s Parallel Evolution

The UK’s Procurement Act 2023 represents one of the most radical domestic overhauls of public procurement in decades. It mandates explicit disclosure of how criteria are scored, requires publication of assessment summaries, and codifies sustainability weightings across NHS tenders.

Within the NHS, a minimum 10% weighting for Net Zero and Social Value now applies to every procurement. Carbon-reduction plans, Evergreen assessments, and sustainability reporting are no longer optional. They are built into the tender architecture itself.

Together, these frameworks establish a common European pattern: the value of non-price performance is measurable, visible, and monetisable.

The New Currency: Data

Structured Publication and Richer Fields

Modern eForms have transformed how procurement information is disclosed. Each notice now encodes detailed fields such as criteria, weights, lots, award values, tender counts, and sub-criteria explanations. The TED data model and UK equivalents capture information that once existed only in static PDFs.

For suppliers, this structured data is a goldmine. It enables systematic tracking of how often certain criteria appear, which buyers assign weight to quality versus sustainability, and how these preferences evolve by product category or geography.

When combined across thousands of tenders, the resulting dataset reveals a live map of market expectations, not just what buyers buy, but what they value.

Policy-Driven Weightings

Different jurisdictions shape the landscape with their own policy signals.

• NHS England’s Net Zero & Social Value weighting embeds environmental and community considerations into procurement.
• France’s Code de la Commande Publique requires life-cycle cost considerations and social inclusion metrics.
• Germany’s Vergaberecht increasingly supports innovation and environmental criteria in healthcare procurement.

The outcome is consistent: buyers are compelled to quantify non-price dimensions. Suppliers that can match evidence to these weightings gain a measurable advantage.

The economics of healthcare are shifting faster than most systems can keep pace. Inflation continues to drive production costs upward. Payers are enforcing stricter reimbursement thresholds. Health technology assessment frameworks are expanding, requiring clearer evidence of value and outcomes. Across global markets, transparency laws and data-sharing mandates are tightening around every pricing decision.

Against this backdrop, pharmaceutical and MedTech companies face a defining question: how can pricing become a source of stability and growth, rather than a pressure point on profitability?

The answer lies in intelligence, not the anecdotal kind drawn from intuition or past experience, but structured, predictive, and adaptive intelligence.

This is the foundation on which Vamstar’s Pricing AI and Value AI platforms have been built. These solutions combine curated life sciences data, machine learning, and automation to create an entirely new category of commercial capability: AI-powered pricing orchestration.

By turning unstructured data into actionable insights, they help pricing and access teams anticipate change, model outcomes, and act with precision before market forces dictate the result.

The Cost of Standing Still

Traditional pricing methods, while once sufficient, now carry enormous opportunity costs. Manual processes anchored in spreadsheets and legacy revenue-management tools cannot model the complexity of today’s global markets.

Formulas become misaligned. Exchange rates fluctuate. Competitor strategies shift overnight. And while finance and access teams scramble to reconcile data from multiple systems, critical opportunities pass unnoticed.

At best, this results in sluggish responses to tender requests and payer demands. At worst, it leads to systematic revenue leakage, over-discounting, or loss of reimbursement.

The tools many organisations still depend on were never designed for continuous adaptation. They offer governance but not foresight, structure but not intelligence. The time has come for pricing to move from reactive management to proactive strategy.

Why AI and Data Are the Missing Ingredients

The global market for pharmaceuticals and medical devices now operates under an unprecedented level of transparency. Governments and payers compare prices across borders. Procurement agencies use digital marketplaces that expose competitive benchmarks in real time.

In this new environment, pricing must be rooted in evidence and defended with data.

Vamstar’s approach to AI in pharmaceutical pricing bridges this gap. The company has developed a connected data and intelligence ecosystem that spans the entire pricing lifecycle. By aggregating and enriching thousands of structured and unstructured datasets, from tender archives and HTA reports to policy signals and reimbursement trends, Pricing AI and Value AI transform complexity into clarity.

This capability allows teams to:

• Detect patterns and anomalies in pricing decisions across geographies and product portfolios.
• Simulate the financial and market impact of proposed price changes.
• Correlate payer behaviour with clinical and economic outcomes.
• Generate scenario-based recommendations that align pricing strategy with organisational objectives.

What emerges is a continuous feedback loop that empowers teams to act confidently and defend every pricing decision with quantifiable evidence.

Inside Vamstar’s Pricing Intelligence Engine

• Step 1: Assembling and Refining the Dataset

Every pricing strategy begins with data, but in most organisations, that data is fragmented across multiple systems. Publicly available databases, payer websites, and regional tender platforms provide valuable information, yet it is inconsistent and rarely optimised for life sciences use.

Our data scientists solve this through extensive collection, harmonisation, and validation. They transform these disparate sources into a single proprietary dataset that captures market share, product penetration, price evolution, and payer activity at global scale.

This curated dataset becomes the backbone of the Polaris pricing engine, designed to deliver precision in modelling and adaptability in decision-making.

• Step 2: Harnessing the Power of Predictive and Agentic AI

With this foundation in place, AI models trained specifically on lifesciences data take the lead. Polaris, the technology underscoring Pricing and Value AI, uses predictive analytics to identify the relationships between discount structures, market access decisions, and competitor behaviour.

Meanwhile, Value AI integrates the evidence layer, connecting clinical outcomes, HTA assessments, and policy frameworks to build a complete picture of value.

Together, these systems do more than analyse. They learn. They detect subtle signals in the data, policy shifts, reimbursement trends, payer sentiment and adjust their recommendations automatically.

This is the essence of Agentic AI: intelligence that not only interprets information but acts on it, guiding pricing and access teams toward the most advantageous course of action.

• Step 3: Turning Insight into Action

The final piece of the puzzle is execution. Insights are only valuable when operationalised.

Polaris automates key workflows such as scenario modelling, approval routing, and pricing governance.

The result is a centralised environment where data, intelligence, and action co-exist.

Dashboards provide instant visibility into price performance and highlight deviations that may signal risk or opportunity. When negotiations begin, teams no longer rely on assumptions. They enter discussions equipped with verifiable, evidence-backed data that strengthens their position and accelerates consensus.

How AI Helps Commercial Teams Choose Smarter, Not Just Faster

In tendering, the decision to respond or not respond is the most strategic moment in the entire contracting process. It determines how your organisation spends its time, how effectively it uses data, and ultimately, how often it wins.

Across Europe’s MedTech and Pharma sectors, where tender volumes are high and timelines tight, Go / No-Go decisions are still made the old-fashioned way, hurriedly, subjectively, and without the benefit of historical evidence.

AI is changing that.

The Forgotten Gate in Commercial Decision-Making

Every tender triggers the same question: Do we go for it?

It’s deceptively simple, yet it’s where most inefficiency starts. Without a structured decision process, commercial teams waste time on low-probability opportunities or overlook the ones where they already have an advantage.

Many organisations still base Go / No-Go decisions on instinct. A sales lead likes the account. A territory manager insists “we can make it fit.” Before long, the team is halfway through writing a 200-page submission for a tender they were never positioned to win.

The result: lower win rates, burnout, and lost focus.

The Go / No-Go stage should act as an investment checkpoint, not a box-ticking exercise.

Defining the Go / No-Go Decision

A Go / No-Go decision evaluates whether a tender aligns with your strategic objectives, product readiness, and competitive position. It’s an internal checkpoint to determine if the opportunity is worth pursuing.

In high-performing commercial teams, this step is formalised, data-informed, and built into the tendering workflow. AI plays a crucial role by making the decision fast, consistent, and evidence-based.

Just a few months ago, we examined the seismic implications of the Trump administration’s proposed tariffs on branded pharmaceuticals and medical technologies. Our analysis focused on the potential disruptions to global supply chains, the risks of escalating trade frictions, and the strategic recalibrations life sciences companies would need to consider. Since then, events have moved rapidly and the terrain looks increasingly complex.

The Pfizer Deal: Catalyst or Exception?

The breakthrough moment came with Pfizer’s agreement to a three-year tariff grace period in exchange for lowering drug prices under Medicaid and participating in the new TrumpRx direct-to-consumer platform. Market reaction was immediate: pharma equities surged, relieved that the specter of across-the-board tariffs was replaced, at least temporarily, by a negotiated framework.

But this deal is more than a headline. It establishes a blueprint, an implicit message that tariff exposure can be negotiated away, provided companies accept pricing concessions or commit to U.S. investment. For Pfizer, the financial impact may be modest given Medicaid’s existing discounts, but the political symbolism is substantial.

Expanding the Net: From Pharma to MedTech

While much attention has focused on branded drugs, the tariff lens has widened. The administration has signaled scrutiny of medical devices, diagnostics, and even biotech supply chains, with probes initiated into sectoral reliance on imports. MedTech manufacturers, historically less exposed to U.S. pricing reform than pharma, may now find themselves navigating both tariff threats and cost-down pressures.

This shift underscores a critical reality: tariffs are not a pharma-only story. The life sciences ecosystem, from reagents to robotics, is increasingly entangled in the broader “onshoring” agenda.

Investments as Insurance

In parallel, industry giants are pledging record U.S. investments. Roche has committed $50 billion, AstraZeneca the same, and Novartis over $20 billion — each linking their announcements explicitly to U.S. tariff risk. These capital deployments serve both political optics and operational hedging, positioning firms as partners in America’s industrial renewal while securing carve-outs from punitive tariffs.

For smaller biotech and medtech firms, however, replicating such moves is far from feasible. Without balance sheet scale, they face the dual challenge of navigating tariffs while preserving financial viability. Strategic partnerships, contract manufacturing alliances, and digital efficiency gains may be the only sustainable hedge.

And what a vertical, tender-aware, evidence-linked approach (like Vamstar’s) does differently.

Generic price-optimisation platforms—built for retail, travel, or horizontal B2B—struggle in Pharma, MedTech, and Biotech because the optimisation problem is fundamentally different. Life-sciences pricing is constrained by tender mechanics, external/ international reference pricing (ERP/IRP), health technology assessment (HTA) and value-based procurement (VBP), and policy shocks. These conditions demand models that read policy and tender text, simulate sealed-bid outcomes, respect cross-border price linkages, and integrate clinical-economic value. Horizontal tools are not designed for this.

Life-sciences pricing is not a retail problem

Tender-driven demand. In many markets, a single national or regional tender sets price and volume for years; the “demand curve” is discontinuous and winner-takes-most. Standard elasticity models learned from high-frequency, transactional data don’t apply. IQVIA’s landscape review shows tendering dominates procurement for originals, biosimilars, generics, and vaccines across Europe.

ERP/IRP linkages. Dozens of countries peg price ceilings to baskets of other countries; a move in one market can cascade through others. OECD and peer-reviewed reviews document the pervasiveness of IRP/ERP and the spillovers this creates. Any optimiser that maximises local revenue without ERP constraints risks triggering cross-market price compression.

HTA and cost-effectiveness. In the UK and other systems, HTA (e.g., NICE) evaluates clinical and cost effectiveness; funding and price are tied to value and ICERs, not just willingness to pay. Optimisation must ingest HTA guidance and thresholds.

VBP and MEAT scoring. In devices especially, contracts are awarded on most economically advantageous tender (MEAT)—a weighted score across price, outcomes, quality, total cost of care, sustainability—not lowest price. Price is one factor in a multi-attribute auction.

Centralised buyers. Saudi Arabia’s NUPCO and GCC joint procurement concentrate demand and enforce framework agreements—massively altering pricing power and the bid calculus.

Tendering is an auction, not “dynamic pricing”

Hospital and payer tenders are often first-price sealed-bid or multi-winner procurement auctions with quality/technical scoring. Optimal bidding here requires bid-shading under uncertainty, competitor count modelling, and winner’s-curse mitigation—concepts from auction theory that generic retail/ticketing optimisers simply don’t implement.

Empirical work on procurement shows:

• • Additional competitors reduce prices materially (≈5% per extra bidder in analogue drug tenders).
  • “Winner’s curse” dynamics are real in procurement (under-estimating costs → unsustainable bids → supply risk).

If your optimiser cannot simulate sealed-bid tender outcomes with quality weights, it will over- or under-shade bids and destroy margin or lose share.

The data-generating process is sparse, policy-constrained, and text-heavy

Sparse events. Many SKUs face a handful of lumpy tenders per year—not millions of daily transactions. Models must learn from low-frequency, high-stakes events and transfer learn across countries and lines, not from clickstreams.

Text is the spec. Eligibility clauses, service levels, penalties, and equivalence rules live in PDFs and portals, not neat columns. Optimisers must parse and reason over tender/contract text—not just numbers. (Generic tools rarely read source tender documents.)

Policy shocks. Procurement rules change quickly: e.g., the EU recently barred most Chinese medical-device bids over €5m under the International Procurement Instrument—instantly altering feasible supplier sets and price baselines. Optimisers must incorporate such shocks into scenario planning.

Supply fragility. Aggressive price pressure can induce shortages; recent reporting shows shortages in essential generics when economics turn non-viable. Optimisers need guardrails for sustainable pricing, not just lowest bid.